Aura Biosciences Inc - Asset Resilience Ratio
Aura Biosciences Inc (AURA) has an Asset Resilience Ratio of 60.16% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore Aura Biosciences Inc total assets for the complete picture of this company's asset base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how Aura Biosciences Inc's Asset Resilience Ratio has changed over time. See Aura Biosciences Inc net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Aura Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Aura Biosciences Inc worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $114.31 Million | 60.16% |
| Total Liquid Assets | $114.31 Million | 60.16% |
Asset Resilience Insights
- Very High Liquidity: Aura Biosciences Inc maintains exceptional liquid asset reserves at 60.16% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Aura Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Aura Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 13.57% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 82.25% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Aura Biosciences Inc (2021–2024)
The table below shows the annual Asset Resilience Ratio data for Aura Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 65.42% | $119.40 Million | $182.50 Million | -7.14pp |
| 2023-12-31 | 72.56% | $185.09 Million | $255.07 Million | +42.54pp |
| 2022-12-31 | 30.02% | $67.23 Million | $223.94 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $160.03 Million | -- |
About Aura Biosciences Inc
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the … Read more